Compare WFF & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFF | QNRX |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 10.1M |
| IPO Year | 2025 | N/A |
| Metric | WFF | QNRX |
|---|---|---|
| Price | $0.40 | $9.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 191.2K | 33.1K |
| Earning Date | 12-31-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,021,079.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.45 | N/A |
| 52 Week Low | $0.38 | $5.01 |
| 52 Week High | $29.26 | $41.80 |
| Indicator | WFF | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | 34.01 |
| Support Level | $0.38 | $9.59 |
| Resistance Level | $0.51 | $11.88 |
| Average True Range (ATR) | 0.04 | 0.84 |
| MACD | -0.00 | -0.28 |
| Stochastic Oscillator | 8.52 | 2.95 |
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.